Steven Cohen’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.42M Buy
+34,400
New +$7.46M 0.01% 1394
2026
Q1
Sell
-4,400
Closed -$804K 3780
2025
Q4
$804K Hold
4,400
﹤0.01% 2993
2025
Q3
$534K Hold
4,400
﹤0.01% 1898
2025
Q2
$459K Sell
4,400
-200
-4% -$21.2K ﹤0.01% 1814
2025
Q1
$536K Buy
+4,600
New +$524K ﹤0.01% 1615
2024
Q4
Sell
-10,900
Closed -$980K 2079
2024
Q3
$980K Hold
10,900
﹤0.01% 1424
2024
Q2
$877K Buy
10,900
+2,500
+30% +$185K ﹤0.01% 1304
2024
Q1
$670K Buy
+8,400
New +$705K ﹤0.01% 1564

Other funds holding AXSM

Steven Cohen's AXSM Position: Q2 2026 in Review

Steven Cohen reduced its Axsome Therapeutics (AXSM) stake by 1.9% in Q2 2026, selling an estimated $1.79M and leaving 416,516 shares worth $102M. The position accounts for 0.11% of the portfolio, ranked #199.

Steven Cohen first reported a position in AXSM in Q4 2018 and has held it in 24 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Steven Cohen held 416,516 shares of Axsome Therapeutics worth $102M as of Q2 2026.
  • Steven Cohen sold 8,234 Axsome Therapeutics shares in Q2 2026, an estimated $1.79M.
  • Axsome Therapeutics made up 0.11% of Steven Cohen's portfolio in Q2 2026, its #199 holding.
  • Steven Cohen first reported a position in Axsome Therapeutics in Q4 2018 and has held it in 24 quarters since.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.